Analysts Expect Atossa Genetics Inc (ATOS) to Announce ($0.74) Earnings Per Share

Atossa Genetics Inc (NASDAQ:ATOS) has received an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Brokerages have set a 12-month consensus target price of $10.00 for the company and are forecasting that the company will post ($0.74) EPS for the current quarter, according to Zacks. Zacks has also assigned Atossa Genetics an industry rank of 101 out of 255 based on the ratings given to its competitors.

Several equities research analysts have issued reports on ATOS shares. Noble Financial set a $10.00 target price on shares of Atossa Genetics and gave the stock a “buy” rating in a research note on Tuesday, May 15th. Maxim Group set a $10.00 target price on shares of Atossa Genetics and gave the stock a “buy” rating in a research note on Monday, May 14th. Finally, ValuEngine raised shares of Atossa Genetics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

Atossa Genetics traded down $0.09, reaching $2.51, during trading on Friday, Marketbeat Ratings reports. The company had a trading volume of 161,148 shares, compared to its average volume of 393,423. Atossa Genetics has a 1-year low of $2.51 and a 1-year high of $19.08.

Atossa Genetics (NASDAQ:ATOS) last announced its earnings results on Monday, May 14th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.15. analysts forecast that Atossa Genetics will post -3.69 EPS for the current year.

Atossa Genetics Company Profile

Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.

Get a free copy of the Zacks research report on Atossa Genetics (ATOS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with's FREE daily email newsletter.

Leave a Reply